There is no established protocol proven to be beneficial for treatment of hepatocellular carcinoma recurrence after liver transplantation. Only a few reports have shown direct treatment by surgery or ablation to be independent predictors of survival for localized recurrence. Moreover, the necessity of immunosuppression to prevent allograft rejection makes many physicians hesitate to administer systemic chemotherapy. This case report documents a case in which the administration of an herbal product, an extract of the lacquer tree, Rhus verniciflua Stokes, was associated with a decrease in the size of lung metastases in a patient with recurrent hepatocellular carcinoma after liver transplantation refractory to doxorubicin. This patient experienced prolonged survival compared with average survival times and little toxicity.
Introduction
Liver transplantation (LT) is a curative treatment for hepatocellular carcinoma (HCC), and in patients with liver cirrhosis, LT has the additional advantage of replacing the cirrhotic liver. However, recurrence rates are variable with a range of 10% to 20% with dismal prognosis. [1] [2] [3] [4] [5] The median survival of patients with recurrent HCC with extrahepatic metastases is 4 to 9 months despite palliative chemotherapy. 4 Because most patients with posttransplantation recurrences of HCC suffer extrahepatic metastases and multifocal lesions, they have few treatment options and may not be amenable to local therapy. 1, 2, 4 Moreover, data regarding the natural history and appropriate treatment for recurrent HCC after LT are scant. Systemic chemotherapy would be expected to be poorly tolerated by patients because of their need to take immunosuppressant medications to prevent allograft rejection. Therefore, a novel therapeutic strategy with less toxicity and higher efficacy is required for improving survival of patients with recurred HCC after LT.
Herbal medicine is often used for cancer patients as alternative and complementary treatments with wide public acceptance in Korea. Here, we present the case of a patient with recurrent HCC after LT who responded positively to administration of an herbal medicine product, an extract of the lacquer tree, Rhus verniciflua Stokes (RVS).
Case Report
A 62-year-old Korean man was referred to the M . m Integrative Cancer Center, East West Neo Medical Center, Kyunghee University (South Korea) for recurrent HCC with previous failure of doxorubicin after living donor LT in July 2006. He had been diagnosed with hepatitis C infection in 1977 and thereafter progressed to end-stage liver disease. His social history did not include notable alcohol use or smoking. A review of his family history was unremarkable. During routine examination, HCC was found in his liver in January 2005. He underwent living donor LT for both HCC and end-stage liver disease in March 2005. Unfortunately, in September 2005, 6 months after LT, the HCC recurred as multiple metastases in both lungs that were detected by computed tomography (CT) and positron emission tomography (PET). Although pathological confirmation of these lung nodules was not performed, we concluded that the lung lesions were metastatic nodules from HCC based on the radiologist's opinion and the fact that there was no evidence of opportunistic infection, that is, negative culture results for bacteria and fungus and negative results on serologic studies for viral infection. The patient was taking cyclosporine as an immunosuppressant at the time of recurrence. A CT scan performed after 3 months of systemic doxorubicin chemotherapy showed progression of his lung metastases. Grade 4 neutropenia developed after chemotherapy according to common terminology criteria for adverse events (CTCAE) v 3.0. Because the patient was not gaining any clinical benefit from conventional systemic chemotherapy and increased morbidity, his physicians decided not to administer any more systemic chemotherapy and to observe the lung metastases carefully.
When the patient initially visited our institution, liver function tests and complete blood cell count were within the normal range, and his a-fetoprotein (AFP) was 67 ng/ mL (normal range = 0-7 ng/mL). His lung metastases on CT scan in June 2006 had progressed compared with those seen on CT scan in April 2006 ( Figure 1 ). On July 7, 2006, the patient began receiving oral RVS extract, 450 mg 3 times daily, for recurrent HCC. A CT scan and chest X-ray in December 2006, obtained 5 months after the initiation of treatment with RVS extract, showed marked shrinkage of the lung metastases (Figures 1 and 2) . Moreover, the patient tolerated the RVS well, without hematologic and nonhematologic toxicity, and demonstrated a decrease in his AFP level to 6.8 ng/mL. However, after another 4 months of taking the RVS extract, his lung metastasis in the right lower lobe of lung had increased as seen on CT scan on April 7, 2007, and his AFP was elevated to 52 ng/mL. The patient discontinued the RVS extract and underwent intensity-modulated radiation therapy (IMRT) for his lung metastases at his insistence. In June 2007, after finishing IMRT, he developed new liver metastases and his clinical status declined. He was managed with supportive care and died of progressive disease in November 2007.
Rhus verniciflua Stokes Extract
Because the urushiol in RVS causes contact sensitivity, urushiol-free RVS extract is used at the M . m Integrative Cancer Center. The extract was manufactured as follows: 10 kg of fresh RVS was subjected to an allergen removal process according to the method described in Korean Patent No. 0504160, processed into sawdust, and dried. RVS dried sawdust (100 grams) was added to 1.3 L water, and extraction was performed at 100°C and 1 atm for 6 hours. The first extraction afforded 1.12 L of extract, and 1.0 L of 45% (v/v) ethanol was added to the residue left after the first extraction, followed by extraction at 80°C and 0.6 atm for 6 hours. The second extraction afforded 1.05 L of filtrate, which was then mixed with the first extract. The mixture was filtered through a 1 mm microfilter to remove impurities. The obtained filtrate was recovered and concentrated to 20 mL by evaporation under vacuum at 50°C, followed by lyophilization. After drying, 8.8 grams of brown powder was obtained as a product. High-performance liquid chromatography showed that the RVS extract contained fustin, fisetin, sulfuretin, butein, and other compounds. The quality of the extract was tested and controlled according to the standards of the Korean Food and Drug Administration (KFDA) and of our hospital (fisetin >13.0%, fustin >7.0%, urushiol not detected). Daily therapy consisted of taking 1350 mg of orally administered, standardized RVS extract.
Discussion
No optimal treatment modality has been established in locally advanced or metastatic HCC recurrence after LT, although some reports showed surgical treatment was an independent predictor of survival for localized HCC recurrence after LT. 1, 2, 6 Administration of chemotherapy to transplant patients, although possible, has a risk of adverse events because of coadministration of immunosuppressive medications, although some recent retrospective studies suggested palliative chemotherapy was feasible with tolerable toxicity despite unsatisfactory efficacy. 4 Response rates with conventional chemotherapy, generally based on doxorubicin, were around 4% to 24% for patients with locally advanced or metastatic HCC who did not undergo LT. [7] [8] [9] [10] Recently, sorafenib, an oral multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and raf kinase was shown to prolong median survival and time to radiologic progression for nearly 3 months in advanced HCC in a phase III trial. 11, 12 However, this outcome was restricted to advanced HCC, not recurrent HCC after LT. The enrollment of these patients into clinical trials with new approaches would seem reasonable, but in many clinical trials, patients who have undergone liver transplantation are ineligible. Here, we described an interesting case of posttransplant, recurrent HCC responding to the herbal medicine product, RVS extract, with little or no toxicity. The health care system of South Korea has 2 separate medical systems, in which orthodox medicine and traditional Korean medicine (TKM) coexist. Legal support of TKM is currently equivalent to that of orthodox medicine. The KFDA has specific processes for the development of new drugs derived from natural products, for example, herbal medicine. The KFDA determines the safety of herbal medicine based on the recommendations of 11 ancient medical books and long-term clinical usage. The drug used in the present study, RVS extract, is prescribed by TKM doctors eligible for the national license examinations for TKM practice after finishing a 6-year training course in a college of oriental medicine.
Rhus verniciflua Stokes (RVS), commonly known as the lacquer tree, is an indigenous East Asian plant. It has been a traditional herbal medicine used to treat cancer in Korea and China since the 15th century ad. The key signal transduction pathways implicated in the pathogenesis of HCC include PI3K/Akt signaling and VEGF signaling cascades, 11 and recently, RVS extracts have been found to have various biological activities, including antiproliferative and apoptotic activities in human cancer cell lines, inducing apoptosis via activation of caspase-9 and inhibition of the PI3K-Akt/ PKB pathway. [13] [14] [15] [16] [17] [18] [19] These appealing preclinical data support the possibility of RVS extract having clinical and biological effects useful for the treatment of recurrent HCC after LT. The medical application of RVS has been limited because it contains a toxic allergen, urushiol, which is the same irritating substance found in related plants such as poison ivy and poison oak. [20] [21] [22] Therefore, urushiol-free RVS extract has been developed. The drug used in the current study is a standardized, quality-controlled, herbal medicine from which the urushiol has been removed.
An interesting point in this case is that besides the fact that the patient experienced prolonged survival compared with average survival times reported in the literature, the administration of RVS extract was associated with a decrease in the size of the patient's lung metastases from recurrent HCC after LT refractory to doxorubicin. Progression-free survival and overall survival were 8 and 17 months, respectively. RVS extract is attractive as a treatment option because it has little if any toxicity. In the context of previous reports describing the outcomes of unresectable, recurrent HCC after LT, the treatment outcome of our patient was relatively favorable. Moreover, this patient was refractory to the chemotherapeutic agent, doxorubicin.
Based on the traditional medical literature, preclinical and clinical observations, RVS extract has often been prescribed for cancer patients who are refractory to or ineligible for systemic chemotherapy due to comorbidity, poor performance status, old age, or patient's preference. Although this patient had a relatively favorable outcome after treatment with RVS extract, further investigation will be required to determine whether this therapy can be applied with safety and efficacy to other posttransplant patients with recurrent HCC.
